Oncotarget

Research Papers:

Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion

Stefan Steurer, Lara Schwemmer, Claudia Hube-Magg, Franziska Büscheck, Doris Höflmayer, Maria Christina Tsourlakis, Till S. Clauditz, Andreas M. Luebke, Ronald Simon, Guido Sauter, Jakob Izbicki, Cornelia Schroeder, Thorsten Schlomm, Hartwig Huland, Hans Heinzer, Alexander Haese, Markus Graefen, Cosima Göbel, Sören Weidemann, Patrick Lebok, David Dum, Christoph Fraune, Sarah Minner and Jan Meiners

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2019; 10:7096-7111. https://doi.org/10.18632/oncotarget.27270

Metrics: PDF 1178 views  |   Full Text 1979 views  |   ?  


Abstract

Stefan Steurer1,*, Lara Schwemmer1,*, Claudia Hube-Magg1, Franziska Büscheck1, Doris Höflmayer1, Maria Christina Tsourlakis1, Till S. Clauditz1, Andreas M. Luebke1, Ronald Simon1, Guido Sauter1, Jakob Izbicki2, Cornelia Schroeder2, Thorsten Schlomm4, Hartwig Huland3, Hans Heinzer3, Alexander Haese3, Markus Graefen3, Cosima Göbel1, Sören Weidemann1, Patrick Lebok1, David Dum1, Christoph Fraune1, Sarah Minner1 and Jan Meiners2

1 Institute of Pathology, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

2 General, Visceral and Thoracic Surgery Department and Clinic, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

3 Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany

4 Department of Urology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany

* These authors contributed equally to this work

Correspondence to:

Ronald Simon,email: [email protected]

Keywords: BAP1; prostate cancer; prognosis; immunohistochemistry

Received: June 27, 2019     Accepted: September 24, 2019     Published: December 24, 2019

ABSTRACT

Loss of the putative tumor suppressor BAP1 is a candidate biomarker for adverse prognosis in many cancer types, but conversely for improved survival in others. Studies on the expression and prognostic role of BAP1 in prostate cancer are currently lacking. We used a tissue microarray of 17,747 individual prostate cancer samples linked with comprehensive pathological, clinical and molecular data and studied the immunohistochemical expression of BAP1. BAP1 expression was typically up regulated in cancers as compared to adjacent normal prostatic glands. In 15,857 cancers, BAP1 staining was weak in 3.3%, moderate in 41.6% and strong in 17.4%. Strong BAP1 staining was associated with advanced tumor stage (p<0.0001), high classical and quantitative Gleason grade (p<0.0001), lymph node metastasis (p<0.0001), a positive surgical margin (p=0.0019) and early biochemical recurrence (p<0.0001). BAP1 expression was linked to ERG-fusion type cancers, with strong BAP1 staining in 12% of ERG-negative, but 30% of ERG-positive cancers (p<0.0001). Subset analyses in 5,415 cancers with and 4,217 cancers without TMPRSS2:ERG fusion revealed that these associations with tumor phenotype and patient outcome were largely driven by the subset of ERG-negative tumors. Multivariate analysis revealed that the prognostic impact was independent of established prognostic features in ERG negative p<0.001) but not in ERG positive cancers. BAP1 expression was further linked to androgen receptor (AR) expression: Only 2% of AR-negative, but 33% of strongly AR expressing cancers had strong BAP1 expression (p<0.0001). In conclusion, this study shows that BAP1 up regulation is linked to prostate cancer progression and aggressiveness.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27270